ERBB2 and invasive breast carcinoma: TNBC, accounting for approximately 15% of all invasive breast cancers[1], is a rising burden globally[2,3]; although the cutoffs used to define “positive” vs. “negative” expression of steroid hormone receptors and ERBB2 amplification/overexpression have changed over time[4,5].